• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    AGC Biologics Appoints Jun Takami GM of Chiba Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans

    Alkermes, Merck Enter Clinical Trial and Supply Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Reed-Lane

    Quotient Sciences

    Almac Group

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Quotient Sciences

    Alcami

    Syngene

    Almac Group

    Reed-Lane
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    CrownBio-PRECOS Acquisition

    Crown Bioscience's president talks about this preclinical play

    Related CONTENT
    • Hitachi, Axcelead to Develop Next-Gen Biopharmaceuticals
    • Charles River Acquires Retrogenix
    • Accelerate Your Program: Streamlined Phase Appropriate Technologies & Expertise
    • Eisai Begins Construction of New Injection/Research Building
    • Evotec, Takeda Enter Multi-RNA Target Alliance
    Kristin Brooks08.21.13
    Crown Bioscience, Inc. recently acquired Preclinical Oncology Services Ltd. (PRECOS), a preclinical service provider with expertise in oncology. The acquisition positions Crown among the largest suppliers of oncology services with a global footprint spanning North America, Europe and Asia Pacific. CrownBio provides translational platforms and drug discovery solutions in the therapeutic areas of oncology and metabolic disease.

    Headquartered in Santa Clara, CA, the company also has research facilities in Kannapolis, NC, Beijing and Taicang, China. PRECOS provides reproducible, patient-relevant in vivo and in vitro oncology models as a business unit of the University of Nottingham, UK. In 2010 PRECOS became fully independent to provide commercial service to clients. We spoke with Jean-Pierre Wery, president of Crown Bioscience, regarding the acquisition and how it will affect the two companies. --KB


    Contract Pharma: What was the strategy behind the PRECOS acquisition?
     
    Jean-Pierre Wery: Crown Bioscience specializes in providing unique translational and drug discovery technologies to its partners in two dedicated therapeutic areas: Oncology and Metabolic Diseases. For Oncology we provide an extensive list of technologies covering most needs for pre-clinical drug discovery. Recently there has been a much-heightened interest in translational technologies, which can improve the early selection of compounds and much better probability of success for clinical development. Of particular interest is a platform called PDX (for Patient Derived Xenograft). These animal models have been shown to be extremely predictive of the effect of drugs on human cancers.

    Both Crown and Precos have been working on PDX technologies for several years and have produced very complimentary platforms. Crown has currently the largest collection of PDX models in the world, but most of these models are from Asian origin. Precos has a large collection of Caucasian models and also specialized models such as drug resistant models and metastatic models. Also, the other cancer biology and pharmacology tools developed by each company are very complimentary. Precos also brings important imaging capabilities to the combined companies. Also, in addition to the technological capabilities, there’s also a great deal of complementary business development activities. Crown has been a very dominant service provider in Asia and the United States while Precos is a well-recognized name in Europe. The combined company can provide the best service platforms for preclinical drug discovery and translational sciences for customers worldwide.
     
    CP: What range of services will the combined company offer?
     
    JW: We will be able to offer services for all preclinical needs. Our expertise covers a wide range of activities, from early target discovery and validation to the delivery of a clinical candidate. Our translational technologies enable the discovery of biomarkers to facilitate and improve the probability of clinical development success.
     
    CP: How do the service offerings differ and/or complement existing capabilities for each company?
     
    JW: The biggest impact will be in the area of translational sciences. The increased number of PDX models (and their increased diversity. Asian vs. Caucasian) greatly enhance the ability of the platform to answer critical questions regarding the potential of a new drug candidate and the best clinical path. The development of specialized models (such as resistant models and metastatic models) and the availability of imaging technologies will also greatly enhanced the power of the translational platform.
     
    CP: In what areas do you expect to gain scope/scale as a result of the acquisition?
     
    JW: One particular exciting application of the PDX technology is the possibility of running animal model trials actually mimicking human clinical trials. Since each PDX model represents a patient, if a compound can be tested in a sufficiently large number of models, the data generated can be extremely useful in identifying therapeutic indications and biomarker for patient selection. Recent experiments have demonstrated that these animal models trials can be very predictive of what will happen in the human clinical trial. Of course, the use of such approach requires the availability of a large and diverse collection of PDX models in order to generate meaningful data and correctly sample the targeted patient populations. The combination of Crown and Precos PDX models platforms has created the largest and most diverse PDX collection in the world. Also, because of the scale of our operations, we can keep many models “live” and immediately available for use. This enables us to complete a trial in just a few months instead of a year or more. This timely data generation is critical to ensure that the information will impact the design of the clinical development of a new drug candidate.
     
    CP: Will PRECOS run separately or operate under a single CrownBio business model?
     
    JW: After an appropriate integration period, both companies will run under a single business model.
     
    CP: In what other areas is CrownBio looking to grow, either internally or via acquisition?
     
    JW: We are passionate about making the drug discovery and development process more efficient and more successful in areas of Oncology and Metabolic Diseases where many unmet medical needs still exists. This led us to focus our R&D efforts on the development of improved translational technologies. Other areas of interest for us are target identification/validation, lead optimization, biomarker identification and validation. We will continue our internal research efforts in these areas but we will also look at external opportunities.
     
    CP: Are there geographic regions of growth that you're trying to reach?
     
    JW: We currently have customers in all major markets around the world. We are of course interested in continuing to improve our market share in each area and to make our technologies available to as many customers as possible.
     
    CP: Are you seeing an increase in preclinical outsourcing? If so, what specific areas?
     
    JW: Yes, we are seeing changes in the types of services that organizations are outsourcing and their frequency. There is a more sophisticated use of external partners and the models chosen. For example, in 2013 the growth in the use of PDX for oncology has been dramatic as research organizations look to use more patient-relevant models to screen their candidates in the preclinical setting.
     
    CP: What are some market trends in preclinical outsourcing?
     
    JW: In oncology and metabolic diseases, the current market trend is clearly towards more patient-relevant models and translational platforms that enable efficacy testing based on patient stratification. Many clients now generate their own biomarker fingerprints to select responders and non-responders in a population, so having access to large collections of well-characterized models that more closely relate to the patient condition in the clinic is key in enabling them to find models, which are relevant to use for screening.


    Kristin Brooks is the associate editor of Contract Pharma.
    Related Searches
    • Development
    • Clinical Trials
    • contractpharma.com
    • Testing
    Suggested For You
    Hitachi, Axcelead to Develop Next-Gen Biopharmaceuticals Hitachi, Axcelead to Develop Next-Gen Biopharmaceuticals
    Charles River Acquires Retrogenix Charles River Acquires Retrogenix
    Accelerate Your Program: Streamlined Phase Appropriate Technologies & Expertise Accelerate Your Program: Streamlined Phase Appropriate Technologies & Expertise
    Eisai Begins Construction of New Injection/Research Building Eisai Begins Construction of New Injection/Research Building
    Evotec, Takeda Enter Multi-RNA Target Alliance Evotec, Takeda Enter Multi-RNA Target Alliance
    High Purity New England & Univercells Technologies Unveil Bioprocessing Solutions High Purity New England & Univercells Technologies Unveil Bioprocessing Solutions
    Jubilant Therapeutics Appoints Chief Scientific Officer Jubilant Therapeutics Appoints Chief Scientific Officer
    Reshaping the Pharmaceutical Supply Chain Reshaping the Pharmaceutical Supply Chain
    High Purity New England Bolsters Biopharma Solutions Services High Purity New England Bolsters Biopharma Solutions Services
    Eurofins Scientific Acquires Beacon Discovery Eurofins Scientific Acquires Beacon Discovery
    Drug Discovery Chemistry Drug Discovery Chemistry
    Aerosol Delivery Devices Market Aerosol Delivery Devices Market
    BioDuro-Sundia Appoints CEO BioDuro-Sundia Appoints CEO
    Sai Life Sciences Expands Capabilities Sai Life Sciences Expands Capabilities
    X-Chem Acquires IntelliSyn and AviSyn X-Chem Acquires IntelliSyn and AviSyn

    Related Online Exclusives

    • Clinical Trials | Drug Development | QA/QC
      RBQM Comes of Age: COVID as a Catalyst for Change

      RBQM Comes of Age: COVID as a Catalyst for Change

      Clinical trial conduct has undergone a fundamental shift over the last year – and things will never be the same again.
      Kristin Brooks, Managing Editor 04.01.21

    • Biologics, Proteins, Vaccines | Clinical Trials
      Inside a COVID Vaccine Trial

      Inside a COVID Vaccine Trial

      Dr. Murphy of ICON, provider of clinical services to Pfizer/BioNTech’s COVID vaccine program, discusses what it takes to conduct a vaccine trial of this scale.
      Kristin Brooks, Managing Editor 02.05.21

    • Clinical Trials | Information Technology
      The State of Clinical Trial Technology

      The State of Clinical Trial Technology

      Blake Adams of Florence discusses key report findings and the clinical trial software used to support Pfizer’s global COVID-19 vaccine study.
      Kristin Brooks, Contract Pharma 01.26.21


    • Analytical Services | Laboratory Testing
      Improving Product Profitability

      Improving Product Profitability

      Using PAT/QbD/CM as tools to increase profitability of products.
      Emil Ciurczak, Contributing Editor 01.21.21

    • Clinical Trials | Drug Development | Information Technology
      Advancing Digital Endpoints in Clinical Trials

      Advancing Digital Endpoints in Clinical Trials

      An end-to-end approach to managing wearable devices through clinical development.
      Kristin Brooks, Contract Pharma 12.14.20

    • Clinical Trials | Drug Development | Preclinical Outsourcing
      Accelerating R&D Trends

      Accelerating R&D Trends

      The pandemic has propelled lingering trends into the forefront and increasingly complex molecules and biologics have drug developers outsourcing more.
      Kristin Brooks, Contract Pharma 10.20.20


    • Biologics, Proteins, Vaccines | Drug Discovery
      Cell Therapy for Solid Tumors

      Cell Therapy for Solid Tumors

      Is base editing the solution for solid tumor-based cell therapy?
      Jonathan Frampton, Corporate Development Partner, Horizon Discovery 06.26.20

    • Analytical Services | Biologics, Proteins, Vaccines | Drug Development | Drug Discovery | Laboratory Testing
      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      Responding to demand for challenging assays and custom solutions required for complex molecules, biologics, vaccines and other innovative therapies.
      Kristin Brooks, Contract Pharma 06.22.20

    • Clinical Trials
      Impact of COVID-19 on Winning New Business

      Impact of COVID-19 on Winning New Business

      WuXi Clinical’s Vice President of Biometrics, David Ng, talks about the impact of COVID-19 on clinical trials and business relations
      Tim Wright, Editor, Contract Pharma 06.03.20


    • APIs | cGMP Manufacture | Clinical Trials | Supply Chain
      Evaluating Pharma Amid COVID-19

      Evaluating Pharma Amid COVID-19

      Dr. Ural of Ernst & Young LLP discusses market dynamics, enduring therapeutic areas, near term M&A, and how industry can use this time for transformation
      Kristin Brooks, Contract Pharma 05.18.20

    • Clinical Trials
      Pioneering Medicine Forward

      Pioneering Medicine Forward

      May 20th marks Clinical Trials Day, celebrating 273 years of clinical trials
      Tina Bland, Senior Consultant, KCR Trial Execution Consulting 05.18.20

    • Clinical Trials | CRO News | Drug Development | Information Technology | R&D
      CRO Industry Update

      CRO Industry Update

      Serge Bodart of IDDI provides insight on the pharma and biopharma trends impacting CROs, outsourcing in today’s market, and advances in clinical research.
      Kristin Brooks, Contract Pharma 04.27.20


    • Clinical Trials | Information Technology | QA/QC
      Managing Clinical Trials Amid the Coronavirus Pandemic

      Managing Clinical Trials Amid the Coronavirus Pandemic

      Patrick Hughes of CluePoints discusses the impact on clinical trials and how leveraging data may herald a long overdue paradigm shift in the industry.
      Kristin Brooks, Contract Pharma 04.06.20

    • Biologics, Proteins, Vaccines | cGMP Manufacture | Clinical Trials | Drug Development | Scale-up/Technology Transfer
      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines
      Kristin Brooks, Contract Pharma 04.03.20

    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development
      COVID-19 Vaccine Response

      COVID-19 Vaccine Response

      ICON execs discuss developments in vaccine research efforts and key challenges of delivering a coronavirus vaccine
      Kristin Brooks, Contract Pharma 04.01.20

    Trending
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Alkermes, Merck Enter Clinical Trial And Supply Agreement
    • Ascendia Pharmaceuticals Poised For Expansion
    • Frontage Expands Capabilities At Its Clinical Site In Secaucus, NJ
    Breaking News
    • Bora Pharmaceuticals Adds Roller Compaction Capabilities
    • Ascendia Pharmaceuticals Poised for Expansion
    • Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • AGC Biologics Appoints Jun Takami GM of Chiba Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Chromaflo Technologies Awarded Gold Status CSR Rating by EcoVadis in EMEA
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands Beautiful Fragrance Collection
    What You’re Reading on Happi.com
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login